Elutia Inc. last reported quarterly results on Nov 5, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): diluted EPS of -$0.04. It usually reports 12–44 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 11, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Jan 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 12–44 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 5, 2026
36 days after quarter end
From press release
|
Q3 FY2026
ended Sep 30, 2026
|
—
|
-1
+66.8%
|
-0.04
+78.9%
|
|
Aug 13, 2026
44 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
2
-11.6%
|
-8
+20.4%
|
-0.17
+34.6%
|
|
May 14, 2026
44 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
3
+5.5%
|
-7
-89.9%
|
-0.17
+19.0%
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
3
+16.2%
|
71
+881.3%
|
0.37
-71.3%
|
|
Nov 6, 2025
37 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
3
-9.3%
|
-4
-400.8%
|
-0.19
+42.4%
|
|
Aug 14, 2025
45 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
3
-56.3%
|
-10
+65.9%
|
-0.26
+77.0%
|
|
May 8, 2025
38 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
3
|
-4
|
-0.21
|
|
Feb 3, 2025
34 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
3
-52.1%
|
-9
+2.7%
|
1.29
+420.4%
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ELUT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Silver Spring, MD
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1708527
- Former names
- AZIYO BIOLOGICS, INC. (until Aug 14, 2023)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.